Symbol | Exchange | Currency |
|---|
BioCryst Pharmaceuticals (BCRX) announces that theIsraeli Ministry of Health has accepted the regulatory submission of Orladeyo for the prevention of recurrent attacks in...
KalVista Pharmaceuticals (KALV) announces clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema ((HAE)) at the 12th C1-Inhibitor Deficiency...
Haemonetics (NYSE:HAE): Q4 Non-GAAP EPS of $0.46 misses by $0.21; GAAP EPS of -$0.22 misses by $0.66.Revenue of $225M (-5.7% Y/Y) beats by $2.02M.Shares +2.2% PM.Press Release
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Sell | Strong Sell |
| Technical Indicators | Buy | Buy | Strong Sell | Strong Buy | Strong Sell |
| Summary | Neutral | Neutral | Strong Sell | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,415.45 | 2,437.72 | 2,389.40 | -12.94 | -0.53% | 1.32M | NASDAQ | |||
| 331.08 | 337.55 | 328.72 | -5.67 | -1.68% | 17.03M | NASDAQ | |||
| 55.18 | 57.34 | 51.86 | -3.86 | -6.54% | 165.38M | NYSE | |||
| 222.97 | 228.73 | 209.00 | +0.47 | +0.21% | 5.52M | NYSE | |||
| 0.206 | 0.00 | 0.00 | -0.040 | -16.15% | 45.00M | OTC Markets | |||
| 77.40 | 78.47 | 75.22 | +1.23 | +1.61% | 1.49M | NASDAQ | |||
| 29.06 | 29.34 | 28.99 | -0.22 | -0.75% | 29.69M | NYSE | |||
| 7.11 | 7.59 | 7.09 | -0.55 | -7.18% | 29.08M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.50 | 1.50 | 1.36 | +0.0800 | +5.63% | 13.73M | NYSE | |||
| 0.696 | 0.00 | 0.00 | +0.0027 | +0.39% | 1.86M | NYSE | |||
| 25.16 | 25.65 | 25.12 | -0.51 | -1.99% | 5.00M | NYSE | |||
| 209.32 | 211.62 | 208.23 | -0.74 | -0.35% | 10.86M | NYSE | |||
| 7.28 | 7.28 | 7.17 | +0.02 | +0.28% | 790.00 | OTC Markets | |||
| 17.65 | 18.36 | 16.53 | -0.63 | -3.45% | 3.50M | NASDAQ |
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
